Acute facial neuralgia related to initiation of emtricitabine/tenofovir for HIV PrEP: a report of two cases in a PrEP demonstration trial.
Journal
Sexual health
ISSN: 1449-8987
Titre abrégé: Sex Health
Pays: Australia
ID NLM: 101242667
Informations de publication
Date de publication:
29 Jan 2024
29 Jan 2024
Historique:
received:
24
07
2023
accepted:
09
01
2024
medline:
29
1
2024
pubmed:
29
1
2024
entrez:
28
1
2024
Statut:
aheadofprint
Résumé
Emtricitabine (FTC) and tenofovir disoproxil fumarate (TDF) fixed-dose combination (FTC/TDF) is generally well-tolerated, although treatment-related adverse events have been reported. We report two cases of persons using FTC/TDF PrEP who had acute neuralgia in a Chinese PrEP demonstration trial. Neurological symptoms subsided upon treatment discontinuation. Symptoms were reported as similar to one case's previous experiences with dolutegravir (DTG)+FTC+tenofovir alafenamide (TAF) (for PEP), leading to permanent discontinuation of PrEP. Acute facial neuralgia appears to be a rare idiosyncratic adverse event to FTC/TDF.
Sections du résumé
BACKGROUND
BACKGROUND
Emtricitabine (FTC) and tenofovir disoproxil fumarate (TDF) fixed-dose combination (FTC/TDF) is generally well-tolerated, although treatment-related adverse events have been reported.
METHODS
METHODS
We report two cases of persons using FTC/TDF PrEP who had acute neuralgia in a Chinese PrEP demonstration trial.
RESULTS
RESULTS
Neurological symptoms subsided upon treatment discontinuation. Symptoms were reported as similar to one case's previous experiences with dolutegravir (DTG)+FTC+tenofovir alafenamide (TAF) (for PEP), leading to permanent discontinuation of PrEP.
CONCLUSION
CONCLUSIONS
Acute facial neuralgia appears to be a rare idiosyncratic adverse event to FTC/TDF.
Identifiants
pubmed: 38281491
pii: SH23129
doi: 10.1071/SH23129
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM